
    
      This is an open label type of study having 3 groups of patients: 1st group comprising of
      patients that would undergo allogeneic (donor-derived) mesenchymal stem cell infusion, 2nd
      group that would undergo autologous (patient-derived) mesenchymal stem cells and the third
      group (control group) without any stem cell infusion. All the three groups would have
      standard dose of Immunosuppressive drugs. Initially the investigators want to recruit 10
      patients in each group and would increase the group size if the investigators get promising
      results on the follow up. The investigators plan to follow up the patients upto 1-2 years for
      immune based assays and then continue the follow up for atleast 5 years.
    
  